THC Reduced Naloxone-Precipitated Withdrawal Signs in Methadone-Dependent Rats

A 1975 rat experiment found lower withdrawal scores after acute THC before naloxone challenge in methadone-dependent animals. The result concerns experimentally precipitated signs, not demonstrated treatment of opioid-use disorder in people.

Dependence and withdrawal were induced experimentally

Rats received repeated methadone before an antagonist challenge. The intervention was an acute THC pretreatment before naloxone, compared with a vehicle condition. This sequence differs from observing naturally occurring withdrawal after a person stops an opioid.

Selected signs changed under the protocol

The authors reported a significant reduction in overall abstinence scores and blockade of wet shakes and gastrointestinal signs. Those observations establish a response within that model. They do not show reduced craving, relapse, compulsive use or sustained recovery.

The translational question remains separate

An intervention that suppresses visible withdrawal signs might have other functional or physiological effects. The abstract does not establish human efficacy, safety, dosing or interaction risks. It also does not demonstrate that the underlying opioid dependence was reversed.

Interpreting the evidence

The study supports a narrow preclinical claim about a defined challenge and measured behaviors. It does not justify replacing opioid treatment, altering methadone or using cannabis as a proven withdrawal remedy. The experimental trigger and timing belong alongside the finding.

Related reading: interpreting cannabis tolerance claims.

Research reference

Hine B; Torrelio M; Gershon S (1975). Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC. Psychopharmacology communications. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us